Fig. 4

Effect of G-CSF therapy on Beclin1, LC3-I & II expression in BCAO mice. a Levels of Beclin1 in the ischemic frontal (F _{(2, 9)} = 20.08, p = 0.0005) and middle (F _{(2, 12)} = 47.52, p < 0.0001) region of mouse’s brain on day 4. b Levels of Beclin1 in the ischemic frontal (F _{(2, 7)} = 7.406, p = 0.0187) and middle (F _{(2, 12)} = 4.020, p = 0.0461) region of mouse’s brain on day 7. c Levels of LC3-I in the ischemic frontal (F _{(2, 21)} = 17.81, p < 0.0001) and middle (F _{(2, 15)} = 35.92, p < 0.0001) and LC3-II levels in ischemic frontal (F _{(2, 18)} = 6.711, p = 0.0066) and middle (F _{(2, 24)} = 26.01, p < 0.0001) region of mouse’s brain on day 7. Representative western blots are presented with cropped blot panels showing target protein signals and control (GAPDH) protein signals in separate panels derived from the same gel. Graphs show mean ± SEM. * and # significant compared to sham & vehicle treated groups, respectively by ANOVA and Tukey post hoc tests (n = 5, p < 0.05)